Novartis Ag

Subramanian Karur

Jiping Fu

Zachary Kevin Sweeney

Peichao Lu

Xianming Jin

Guillaume Lapointe

Aregahegn Yifru

Ann Marie Madera

Xiaolin Li

Keith Bruce Pfister

Mahavir Prashad

David Thomas Parker

Joseph Michael Young

Prakash Raman

Yugang Liu

Wooseok Han

Pascal Rigollier

Mohindra Seepersaud

Rui Zheng

Alexey A Rivkin

Meiliana Tjandra

Patrick Lee

Lech Andrzej Ciszewski

Shawn D Britt

Wosenu Mergo

Andrew Weiss

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

Fused indazole pyridone compounds as antivirals

This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria. 

Isoxazole hydroxamic acid compounds as LpxC inhibitors

This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and compositions for treating infections caused by Gram-negative bacteria. 

Isoxazoline hydroxamic acid derivatives as LpxC inhibitors

The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, and A-B are as defined herein, which are non-immunosuppressive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.

Cyclic peptides and use as medicines

The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein the variables R, R, R, R, R, and A-B are defined herein, which are non-immunosuppresive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.

The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

Organic compounds and their uses

Growing community of inventors

Dublin, CA, United States of America

Subramanian Karur